FDA official behind closed doors said puberty blockers are dangerous for transgender youth

Published



A leading endocrinologist with the Food and Drug Administration recommended pursuing approval for puberty blockers for youth with gender dysphoria despite acknowledging that they raised the risk of depression and suicidality, according to internal emails.

Shannon Sullivan, the clinical team leader at the FDA’s Division of General Endocrinology, recommended to her supervisor in January 2022 that the agency approve puberty blockers to treat adolescents with gender dysphoria following a safety review that showed negative mental health results.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.